Investment Thesis
United Therapeutics (UTHR) holds a sizable chunk of the pulmonary arterial hypertension ("PAH") treatment market - the company has been active in this field since its current best-selling drug Remodulin was approved by the FDA back in 2002.
PAH is a rare disease that affects the right side of the heart as it pumps blood to the lungs, putting excess pressure on the pulmonary arteries, which eventually leads to heart failure and death. There is no known cure for the disease, which primarily affects women in their 30s and 40s. Treatments range from